KR20220063162A - 호흡기 병태 치료에 사용하기 위한 tmem16a 조절제로서의 피리딘 유도체 - Google Patents

호흡기 병태 치료에 사용하기 위한 tmem16a 조절제로서의 피리딘 유도체 Download PDF

Info

Publication number
KR20220063162A
KR20220063162A KR1020227006371A KR20227006371A KR20220063162A KR 20220063162 A KR20220063162 A KR 20220063162A KR 1020227006371 A KR1020227006371 A KR 1020227006371A KR 20227006371 A KR20227006371 A KR 20227006371A KR 20220063162 A KR20220063162 A KR 20220063162A
Authority
KR
South Korea
Prior art keywords
hydroxy
compound
amino
methyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227006371A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 콜링우드
크레이그 벅스턴
조나단 데이비드 하그레이브
피터 잉그램
토마스 보리가드 스코필드
압둘 샤이크
크리스토퍼 스팀슨
Original Assignee
티엠이엠16에이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1910607.9A external-priority patent/GB201910607D0/en
Priority claimed from GBGB2005739.4A external-priority patent/GB202005739D0/en
Application filed by 티엠이엠16에이 리미티드 filed Critical 티엠이엠16에이 리미티드
Publication of KR20220063162A publication Critical patent/KR20220063162A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1020227006371A 2019-07-24 2020-07-24 호흡기 병태 치료에 사용하기 위한 tmem16a 조절제로서의 피리딘 유도체 Ceased KR20220063162A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1910607.9 2019-07-24
GBGB1910607.9A GB201910607D0 (en) 2019-07-24 2019-07-24 Compounds
GB2005739.4 2020-04-20
GBGB2005739.4A GB202005739D0 (en) 2020-04-20 2020-04-20 Compounds
PCT/GB2020/051778 WO2021014166A1 (en) 2019-07-24 2020-07-24 Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions

Publications (1)

Publication Number Publication Date
KR20220063162A true KR20220063162A (ko) 2022-05-17

Family

ID=71948615

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227006371A Ceased KR20220063162A (ko) 2019-07-24 2020-07-24 호흡기 병태 치료에 사용하기 위한 tmem16a 조절제로서의 피리딘 유도체

Country Status (16)

Country Link
US (1) US20220235006A1 (https=)
EP (1) EP4003516A1 (https=)
JP (1) JP7583022B2 (https=)
KR (1) KR20220063162A (https=)
CN (1) CN114616226B (https=)
AU (1) AU2020317036A1 (https=)
BR (1) BR112022001164A2 (https=)
CA (1) CA3145120A1 (https=)
CL (1) CL2022000147A1 (https=)
CO (1) CO2022002022A2 (https=)
CR (1) CR20220072A (https=)
IL (1) IL290035A (https=)
MX (1) MX2022000841A (https=)
PE (1) PE20221441A1 (https=)
PH (1) PH12022550181A1 (https=)
WO (1) WO2021014166A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221441A1 (es) * 2019-07-24 2022-09-21 Tmem16A Ltd Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias
WO2026038890A1 (ko) * 2024-08-13 2026-02-19 광주과학기술원 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176767A1 (en) 2003-10-30 2005-08-11 Laval Chan Chun Kong Pyridine carboxamide and methods for inhibiting HIV integrase
US11358947B2 (en) * 2017-04-17 2022-06-14 The Regents Of The University Of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
PE20221441A1 (es) * 2019-07-24 2022-09-21 Tmem16A Ltd Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias

Also Published As

Publication number Publication date
CN114616226A (zh) 2022-06-10
CO2022002022A2 (es) 2022-06-10
CN114616226B (zh) 2025-03-04
CR20220072A (es) 2022-06-29
MX2022000841A (es) 2022-06-08
BR112022001164A2 (pt) 2022-03-15
JP7583022B2 (ja) 2024-11-13
PH12022550181A1 (en) 2023-01-16
JP2022541311A (ja) 2022-09-22
WO2021014166A1 (en) 2021-01-28
US20220235006A1 (en) 2022-07-28
IL290035A (en) 2022-03-01
CA3145120A1 (en) 2021-01-28
EP4003516A1 (en) 2022-06-01
CL2022000147A1 (es) 2022-10-07
AU2020317036A1 (en) 2022-03-17
PE20221441A1 (es) 2022-09-21

Similar Documents

Publication Publication Date Title
US11364246B2 (en) Compounds
US20220235006A1 (en) Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
US20200361871A1 (en) Compounds
US12415793B2 (en) Modulators of TMEM16A for treating respiratory disease
US12552770B2 (en) Compounds for treating respiratory disease
JP7682850B2 (ja) カルシウム活性化クロライドチャネルモジュレーターとしてのピリジン誘導体
HK40069002A (en) Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
HK40067765A (en) Modulators of tmem16a for treating respiratory disease
HK40075169B (zh) 作为钙激活氯化物通道调节剂的吡啶衍生物
HK40075169A (en) Pyridine derivatives as calcium-activated chloride channel modulators
HK40067764A (en) Compounds for treating respiratory disease
HK40067765B (zh) 用於治疗呼吸系统疾病的tmem16a的调节剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601